Patents by Inventor Nicole Kallewaard-LeLay

Nicole Kallewaard-LeLay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neutralizing anti-influenza A antibodies and uses thereof
    Patent number: 11932682
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 19, 2024
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Neutralizing anti-influenza binding molecules and uses thereof
    Patent number: 11926657
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: March 12, 2024
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF
    Publication number: 20240076357
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: September 8, 2023
    Publication date: March 7, 2024
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
  • RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF
    Publication number: 20230365660
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 16, 2023
    Inventors: Nancy ULBRANDT, Nicole KALLEWAARD-LELAY, Andy Q. YUAN, Bettina RICHTER
  • Neutralizing anti-influenza b antibodies and uses thereof
    Patent number: 11787853
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 17, 2023
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary Mcauliffe, Davide Corti, Antonio Lanzavecchia
  • METHOD OF TREATING INFLUENZA A
    Publication number: 20230181735
    Abstract: Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Nicole KALLEWAARD-LELAY, Raburn MALLORY, Gabriel ROBBIE, Song REN
  • RSV-specific antibodies and functional parts thereof
    Patent number: 11661449
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: May 30, 2023
    Assignee: MedImmune Limited
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF
    Publication number: 20230112916
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Application
    Filed: November 11, 2022
    Publication date: April 13, 2023
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Godfrey Jonah RAINEY, Cuihua GAO, Srinath KASTURIRANGAN, Changshou GAO
  • Method of treating influenza A
    Patent number: 11547756
    Abstract: Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 10, 2023
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Raburn Mallory, Gabriel Robbie, Song Ren
  • Neutralizing anti-influenza binding molecules and uses thereof
    Patent number: 11524993
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 13, 2022
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF
    Publication number: 20220098285
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Application
    Filed: October 22, 2021
    Publication date: March 31, 2022
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF
    Publication number: 20220033480
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 3, 2022
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF
    Publication number: 20220025020
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: October 12, 2021
    Publication date: January 27, 2022
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Ebony BENJAMIN, Leslie WACHTER, Andy YUAN, Josephine Mary MCAULIFFE, Davide CORTI, Antonio LANZAVECCHIA
  • Neutralizing anti-influenza A antibodies and uses thereof
    Patent number: 11186627
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 30, 2021
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • RSV-specific antibodies and functional parts thereof
    Patent number: 11186628
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 30, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Neutralizing anti-influenza B antibodies and uses thereof
    Patent number: 11174304
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: November 16, 2021
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • NEUTRALIZING ANTI-INFLUENZA BINDING MOLECULES AND USES THEREOF
    Publication number: 20210079069
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Application
    Filed: December 1, 2020
    Publication date: March 18, 2021
    Inventors: Nicole KALLEWAARD-LELAY, Qing ZHU, Godfrey Jonah RAINEY, Cuihua GAO, Srinath KASTURIRANGAN, Changshou GAO
  • Neutralizing anti-influenza binding molecules and uses thereof
    Patent number: 10882897
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: January 5, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • METHOD OF TREATING INFLUENZA A
    Publication number: 20200397899
    Abstract: Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.
    Type: Application
    Filed: August 4, 2020
    Publication date: December 24, 2020
    Inventors: Nicole Kallewaard-Lelay, Raburn Mallory, Gabriel Robbie, Song Ren
  • RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF
    Publication number: 20200331989
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 22, 2020
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter